Co-funded by the European Union
Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA)
16 janv. 2025 08h00 HE | Emergent BioSolutions
Africa CDC’s support for the MOSA has enabled the enrollment of the first patients at Mbandaka Hospital in Equateur Province, Democratic Republic of Congo.
emerge.png
Emergent BioSolutions Announces the Execution of Contract Options Valued at $67.4 Million to Procure Additional TEMBEXA® (brincidofovir) to Support National Preparedness Efforts
26 sept. 2024 08h05 HE | Emergent BioSolutions
GAITHERSBURG, Md., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) (“Emergent”) today announced that two contract options have been secured to procure additional treatment...